AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00418418 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Bone marrow aspiration (crista iliaca)
Description: The bone marrow is aspirated from the iliac crest (100ml). During the operation the aspirate is transported to the stem cell laboratory, where the sample is centrifugated through Ficoll(Registered Trademark).
Study NCT00418418 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Intramyocardial mesenchymal stem cell transplantation
Description: During the cardiac arrest, stem cells are directly injected to myocardium. The amount of the cells varies individually (5-1000 x 10e6 cells), the cells are diluted in autologous serum (5 ml)
Study NCT00418418 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Intramyocardial injection of autologous serum
Description: Intramyocardial injection of autologous serum is injected during cardiac arrest
Study NCT03430661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Tablet for oral administration (180 mg)
Study NCT02707471 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SM-AET
Description: self-management for improving adherence and reducing symptom interference (SM-AET)
Study NCT02707471 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: general health education
Description: general health education intervention that focuses on improving overall health.
Study NCT02670382 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: EPA
Description: 10 week supplementation
Study NCT02670382 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DHA
Description: 10 week supplementation
Study NCT02670382 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: sunflower oil
Description: 4-week lead-in
Study NCT03040427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F-18 florbetapir
Description: Cardiac PET images will be obtained following injection of F-18 labeled Florbetapir (Trade Name: Amyvid).
Study NCT05604794 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Ketamine-Assisted Psychotherapy (KAP)
Description: KAP consisting of 4-6 guided ketamine sessions with psychotherapy-only visits after dose 1 and 2 and then after every 2 subsequent doses.
Study NCT00923663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 25 mg Lenalidomide p.o. daily for 21 days
Study NCT03165474 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Web-based comic and newsletters
Description: Web-based comic and health messages (child component) and health newsletters (parent component)
Study NCT03165474 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Didactic health information
Description: Didactic health information and resources by email and/or text
Study NCT01833936 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Compex® muscle stimulator
Description: The Compex® muscle stimulator is a commercially available muscle stimulator that is approved by the Food and Drug Administration (FDA), a governmental body. It is not investigational. The investigational part of this study aims to evaluate if the use of muscle simulation after Achilles tendon surgery will reduce calf atrophy.
Study NCT01833936 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: (inactive) muscle stimulator
Description: A placebo (inactive) muscle stimulator, which will be placed immediately following surgery. Eight electrodes will be placed on the lower leg: four electrodes on the gastrocnemius (calf muscle), and two electrodes each on the lateral gastrocnemius (side) and anterior tibialis muscle (front). Subjects will be instructed to use the stimulator for three 20 minute sessions per day.
Study NCT04453800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sofadil【Neu2000KW】
Description: 500mg Intravenous infusion of sofadil starting at 500mg was 500ml，followed by nine intravenous infusions, each 250mg infusion with 250ml sofadil for 5 days, and each interval is 12 hours
Study NCT04453800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofadil
Description: 750mg Intravenous infusion of sofadil starting at 500mg was 500ml，followed by nine intravenous infusions, each 500mg infusion with 250ml sofadil for 5 days, and each interval is 12 hours
Study NCT04453800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofadil
Description: 1500mg Intravenous infusion of sofadil starting at 500mg was 500ml，followed by nine intravenous infusions, each 500mg infusion with 250ml sofadil for 5 days, and each interval is 12 hours
Study NCT04453800 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Saline was administered intravenously
Study NCT04390763 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NIS793
Description: anti-TGFb antibody
Study NCT04390763 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Spartalizumab
Description: anti-PD-1 antibody
Study NCT04390763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: SOC chemotherapy
Study NCT04390763 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine
Description: SOC chemotherapy
Study NCT04390763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: SOC chemotherapy
Study NCT04390763 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nab-paclitaxel
Description: SOC chemotherapy
Study NCT01685853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisacodyl plus PEG-CS
Description: * the day before colonoscopy: 3-4 bisacodyl tablets (according to patient bowel habit) at bedtime~* the morning of colonoscopy: PEG-CS (2 litres) starting 5 hours before the exam
Study NCT01685853 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEG 4 litres split
Description: * the day before colonoscopy: 2 litres of PEG~* the morning of colonoscopy: 2 litres of PEG starting 5 hours before the examination
Study NCT00623597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir
Description: 2.5-3.0mg/kg po bid (starting dose) for 48 weeks
Study NCT00623597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: saquinavir [Invirase]
Description: 50mg/kg po bid (starting dose) for 48 weeks
Study NCT01463514 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Right heart catheterization
Description: Oxygenation and hemodynamic parameters will be assessed during RHC according to standard procedures. All measurements will be noted as usual for PH assessment including: at rest breathing room air, during an oxygen challenge, under vasodilator testing with NO and/or during exercise. Room air, supplemental oxygen and NO will be applied over common breathing mask while patient is in a supine position. Oxygen will be taken as usual from the common adjustable hospital wall access, NO will be taken according to usual clinical practice during RHC from a gas cylinder connected to a reservoir, where adequate ppm concentration can be regulated. A dose of 40 ppm NO will be used according to common practise. Oxygen delivery to maintain the peripheral oxygen saturation between 88% and 90% will be adjusted over a 3 minute period of time.
Study NCT01463514 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Near-infrared spectroscopy
Description: For study purpose, patients will have additional non-invasive NIRS assessment. The measurement will take place during right heart catheterization.
Study NCT03092245 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OctaplasLG
Description: OctaplasLG is given as an infusion when resuscitation fluids are required.
Study NCT03092245 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ringer-Acetate
Description: Ringer-acetate is given as an infusion when resuscitation fluids are required.
Study NCT01136798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: Exenatide or placebo medication administered subcutaneously 5 mcg twice daily for 2 weeks, followed by 10 mcg twice daily for 4 weeks
Study NCT01136798 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Exenatide or placebo medication administered subcutaneously 5 mcg twice daily for 2 weeks, followed by 10 mcg twice daily for 4 weeks
Study NCT01820637 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Boston Scientific DES SFA Paclitaxel-Eluting Self-Expanding Stent System (DES SFA)
Description: Drug-eluting SFA self-expanding stent
Study NCT00583115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gleevec
Description: 260 mg/M2/day, given once daily by mouth
Study NCT01713998 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ulthera System Treatment
Description: Focused ultrasound energy delivered below the surface of the skin
Study NCT01800578 — intervention group
Intervention type: DEVICE
Intervention: monitor for depth of hypnosis
Description: evaluation of depth of hypnosis~--------------------------------------------------------------------------------
Study NCT04071093 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Home Telemonitoring System (HTS)
Description: The HTS consists of an App that daily collects measurements of weight, blood pressure, heart rate and symptoms (checklist of symptoms questions). The HTS processes the data and generates and sends an alert to the physicians if a risk situation occurs (measurements are outside of normal ranges). The App has also an educational functionality that allows learning about lifestyle, self-care and healthy habits for HF patients. For this purpose, the application: a) has a section that answers frequent questions, b) has a question and answer game about HF, and c) sends educational messages to the patients every day.
Study NCT03811834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mobocertinib
Description: Mobocertinib capsule, \[14C\]-Mobocertinib intravenous infusion, \[14C\]-Mobocertinib oral solution.
Study NCT01424176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexpramipexole (dose 1)
Study NCT01424176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexpramipexole (dose 2)
Study NCT00640042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: morphine sulfate extended release capsules
Description: 30 mg, 60 mg, 90 mg, 120 mg morphine will be prescribed by the Investigator in accordance with the AVINZA prescribing information.
Study NCT02631616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somatostatin
Description: Monthly injections of Somatostatin
Study NCT04043806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ELX/TEZ/IVA
Description: Fixed-dose combination (FDC) tablet for oral administration.
Study NCT04043806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVA
Description: Tablet for oral administration.
Study NCT02277587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plenadren
Description: Oral Tablets: 20-25-30 mg
Study NCT02277587 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional glucocorticoid therapy
Description: Oral Tablets: 20-25-30- 37.5 mg
Study NCT03521206 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACP+ programme
Description: Training program for nursing home staff.
Study NCT02311985 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Coagulogram-based protocol
Description: The interventions for this protocol include transfusion of fresh frozen plasma, platelets (random or aphaeresis) and/or cryoprecipitate, based on international normalised ratio (INR), partial thromboplastin time (PTT), platelet count and/or fibrinogen. If INR >1.5 or PTT >50 sec., fresh frozen plasma is administered (dose: 10 mL/Kg); and/or platelets \<50,000/microliter, random or aphaeresis platelets are administered (01 unit/Kg or 01 aphaeresis); and/or fibrinogen \<150 mg/dL, cryoprecipitate is administered (dose: 01 unit/Kg).
Study NCT02311985 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thromboelastometry-based protocol
Description: The interventions for this protocol include transfusion of fresh frozen plasma, platelets (random or aphaeresis) and/or cryoprecipitate, based on rotational thromboelastometry (ROTEM(R)). If CTex \<80 sec. and A10ex >40 mm, then no blood transfusion is performed; when CTex >80s, then fresh frozen plasma is administered (dose: 10 mL/Kg); and/or A10ex \<40 mm or A10fib >10 mm, random or aphaeresis platelets are administered (01 unit/Kg or 01 aphaeresis); and/or A10ex \<40 mm or A10fib \<10 mm, cryoprecipitate is administered (dose: 01 unit/Kg).
Study NCT02311985 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Restrictive strategy
Description: The interventions for this protocol include transfusion of fresh frozen plasma and/or platelets (random or aphaeresis), based on INR and platelet count. If INR >5, fresh frozen plasma is administered (dose: 10 mL/Kg); and/or platelets \<25,000/microliter, random or aphaeresis platelets are administered (01 unit/Kg or 01 aphaeresis).
Study NCT04461314 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: peer-led counselling
Description: About 50 university students will be trained as peer counsellors through a structured training programme. A pre and post and 6-month self-administered questionnaire will be conducted before, immediately and 6-month after the training programme to examine their changes of knowledge and attitudes. A satisfaction survey will also be conducted to measure participants' perception of the quality of the training programme.~Drug-abusing youth and young adults will receive telephone-based, Peer-led Brief Motivational Interviewing (BMI) counselling to rehabilitate from drug abuse. The peer counsellors will give referral advice if the youth and young adult needs appropriate treatment and rehabilitation services.~The drug abusers will be counselled and invited to complete the follow-up questionnaires at 1 week, 1 month, 3 months, 6 months, 9 months and 1 year. Self-reported quitters at 6-month and 1-year follow-ups will be invited to have a urine test to validate the drug abuse abstinence.
Study NCT02410317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Study NCT02410317 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Study NCT02036606 — intervention group
Intervention type: BEHAVIORAL
Intervention: questionary
Study NCT04695314 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Massage
Description: Foot reflexology board (JAPAN TSUBO HH-700) with massage focused at the base of the second and third toes
Study NCT04695314 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Experimental insert
Description: Raised shoe insert, insert used for massage
Study NCT04695314 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Experimental insert
Description: Raised shoe insert, insert used for massage
Study NCT04695314 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sham insert
Description: Flat shoe insert, insert used for massage
Study NCT04695314 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sham insert
Description: Flat shoe insert, insert used for massage
Study NCT01630837 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: frequency of oral hygiene
Description: the frequency of oral hygiene was 12 to 12 hours, 24 to 24 hours, 48 to 48 hours and 72 to 72 hours.
Study NCT02848989 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Qigong Mind-Body Exercise
Description: An exercise program that involves gentle movements combined with breathing/relaxation techniques
Study NCT02433067 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Description: Patients in arm A (interventional) will carry out a physical activity intervention during 3 months. Patients should perform an interval training program on cycle-ergometer during 3 sessions per week.
Study NCT00700518 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo cream
Description: placebo cream applied to 2 adjacent fingers of non-dominant hand one time
Study NCT00700518 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glyceryl Trinitrate
Description: 0.6mg of Glyceryl Trinitrate applied to 2 adjacent fingers on non-dominant hand one time
Study NCT00700518 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glyceryl Trinitrate
Description: 1.2mg Glyceryl Trinitrate topically to 2 adjacent fingers of non-dominant hand one time
Study NCT00700518 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glyceryl Trinitrate
Description: 1.8mg Glyceryl Trinitrate topically to 2 adjacent fingers of non-dominant hand one time
Study NCT00700518 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glyceryl Trinitrate
Description: 2.4 mg Glyceryl Trinitrate topically to 2 adjacent fingers of non-dominant hand one time
Study NCT03421600 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: blue laser imaging
Description: blue laser imaging
Study NCT03421600 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: White light imaging
Description: White light imaging
Study NCT04602039 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bovine Colostrum
Description: Bovine colostrum (Neovite)
Study NCT02604342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alectinib
Description: Participants will receive oral alectinib at a dose of 600 mg twice daily, taken with food until disease progression, unacceptable toxicity, withdrawal of consent or death.
Study NCT02604342 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Participants will receive docetaxel at a dose of 75 mg/m\^2 of body surface area intravenously every 3 weeks, until disease progression, unacceptable toxicity, withdrawal of consent or death.
Study NCT02604342 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Participants will receive pemetrexed at a dose of 500 mg/m\^2 of body surface area intravenously every 3 weeks, until disease progression, unacceptable toxicity, withdrawal of consent or death.
Study NCT04512898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triple therapy for H.pylori
Description: Triple therapy of proton pump inhibitors, clarithromycin and metronidazole.
Study NCT01702519 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nicotine
Description: nicotine transdermal patch
Study NCT03738397 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Extended release tablet
Study NCT03738397 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Dupilumab is administered as a subcutaneous (SC) injection
Study NCT03738397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to dupilumab
Description: Placebo administered as a subcutaneous injection
Study NCT03738397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to upadacitinib
Description: Tablet
Study NCT04248036 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Circle of Security - Parenting, COS-P
Description: Circle of Security - Parenting is a manual-based, psychoeducational intervention program in group that includes 8 group sessions of 90 minutes each.
Study NCT01891656 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: MI is a client centered, directive style of interacting with a person to help explore and resolve ambivalence about change (Miller \& Rollnick, 2002). MI borrows from Client-Centered Counseling in its emphasis on empathy, optimism, and respect for client choice (Rogers, 1961). MI also draws from Self-Perception Theory, which says that a person becomes more or less committed to an action based on the verbal stance he or she takes (Bem, 1972). The effects of MI tend to be in the small-to-medium range when compared to no treatment, and nonsignificant when compared to more extensive treatment.
Study NCT01891656 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Computer
Description: The growing use of technology has led to the development of automated interventions for behavior change, including some that target drug and alcohol use (Elliott, et al, 2008; Lustria, et al, 2009; Revere \& Dunbar, 2001; Walters, et al, 2006) and treatment interest (Lieberman \& Massey, 2008). As discussed by Hester \& Miller (2006), automated interventions have several potential advantages over face-to-face interventions: (I) They require little or no staff contact, which may increase cost-effectiveness; (2) they can allow for automatic data collection and follow-up; and (3) they can be disseminated with little loss of fidelity.
Study NCT02780739 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Training - 48 sessions
Description: Mind Frontiers cognitive training software (Aptima Inc.) is a Wild West-themed Android application played on Nexus 10 tablets. This intervention includes 20 70-min sessions (23.33 hrs) completed over 12 weeks: 1/wk weeks 5-8, 2/wk weeks 9-16. The 6 mini-games, played in random order for 10 min each session, are Ante Up (Tower of London, executive functioning); Irrigator (visuospatial reasoning); Pen 'Em Up (dual task switching, executive function); Supply Run (Keep Track, working memory updating); Riding Shotgun (visuospatial working memory); and Sentry Duty (dual n-back, working memory). There is also a meta-game in which players build a town using resources earned from the mini-games, played for 5 min each session.
Study NCT02433067 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: standard oncologic care